Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg

Expert Opinion on Drug Safety

Volumn 8, Issue 6, 2009, Pages 615-626

  Wesnes, Keith A ^a   Edgar, Chris ^b   Tretter, Reiner N ^c   Bolodeoku, John ^d  

^a CDR House ^*  (United Kingdom)

^b Clinical Trials Consultant   (United Kingdom)

^c Astellas Pharma Global Development   (Netherlands)

^d ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

Author keywords

Cognitive function; Elderly; Overactive bladder; Oxybutynin; Solifenacin

Indexed keywords

OXYBUTYNIN; SOLIFENACIN;

ADULT; AGED; ALERTNESS; ANALYSIS OF COVARIANCE; ARTICLE; ATTENTION; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; EPISODIC MEMORY; EXPLORATORY RESEARCH; FEMALE; HEART RATE; HUMAN; MALE; MOOD; NORMAL HUMAN; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEDATION; SELF CONCEPT; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; VALIDATION STUDY; VOLUNTEER; WORKING MEMORY;

AGED; ATTENTION; COGNITION; COGNITION DISORDERS; CROSS-OVER STUDIES; EXECUTIVE FUNCTION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LEARNING; MALE; MANDELIC ACIDS; MEMORY; MEMORY, SHORT-TERM; MUSCARINIC ANTAGONISTS; NEUROPSYCHOLOGICAL TESTS; PARASYMPATHOLYTICS; PILOT PROJECTS; QUINUCLIDINES; REACTION TIME; RISK; SAMPLE SIZE; TETRAHYDROISOQUINOLINES;

EID: 70449496244     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903260790     Document Type: Article

References (33)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-178 (Pubitemid 34195211)
2. Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2006;25:293
3. Chapple CR, Artibani W, Cardozo LD, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005;95:335-340
4. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-766
5. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-1315
6. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-336
7. Brown JS, McGhan WF, Chokroverty S. Cormordities associated with overactive bladder. Am J Managed Care 2000;6(11): S574-9
8. Anagnostaras SG, Murphy GG, Hamilton SE, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003;6:51-58
9. Katz I, Sands L, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998;46:8-13
10. Donnellan CA, Fook L, McDonald P, Playfer JR. Lesson of the week: oxybutynin and cognitive dysfunction. BMJ 1997;315:1363-1364
11. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006;50:317-326
12. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urology 2005;173:493-498
13. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005;27:144-153
14. Kay G, Kardiasmenos K, Crook T. Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutynin chloride ER on recent memory in older subjects. 36th Annual Meeting of the ICS, Christchurch, New Zealand, December 2006, abstract 87
15. Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003;349(23):2274-2275
16. Womack KB, Heilman KM. Tolterodine and memory: dry but forgetful. Arch Neurol 2003;60:771-773
17. Suzuki M, Noguchi Y, Okutsu H, et al. Effect of antimuscarinic drugs used for overactive bladder on learning in a rat passive avoidance response test. Eur J Pharmacol 2007;557:154-158
18. Maruyama S, Tsukada H, Nishiyama S, et al. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment. J Pharmacol Exp Ther 2008;325:774-781
19. Wesnes K, Simpson PM, Christmas L. The assessment of human information processing abilities in human psychopharmacology. In: Hindmarch I, Stonier PD, editors, Human Psychopharmacology: measures and methods. John Wiley, Chichester, UK 1987;1:79-92
20. Wesnes KA, Ward T, McGinty A, Petrini O. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacol 2000;152(4):353-361
21. Ebert U, Siepmann M, Oertel R, et al. Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. J Clin Pharmacol 1998;38:720-726
22. Ellis JR, Ellis KA, Bartholomeusz CF, et al. Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. Int J Neuropsychopharmacol 2006;9:175-189
23. Wesnes K, Simpson P, Kidd A. An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg s.c. Hum Psychopharmacol 1988;3:27-41
24. Wesnes KA, Simpson PM, White L, et al. Cholinesterase inhibition in the scopolamine model of dementia. Ann NY Acad Sci 1991;640:268-271
25. Kay GG, Wesnes KA. Pharmacodynamic effects of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int 2005;96:1055-1062
26. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974;47:211-218
27. Yong C. Effect of food on the pharmacokinetics of oxybutynin in normal subjects. Pharm Res 1991;8(Suppl):S-320
28. Krauwinkel WJJ, Smulders RA, Mulder H, et al. Effect of age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther 2005;43:227-238
29. De Ridder D. Antimuscarinics and cognitive function. Eur Urol 2006;50:211-212
30. Barker A, Jones R, Simpson P, Wesnes K. Scopolamine-induced cognitive impairment as a predictor of cognitive decline in healthy elderly volunteers. Int J Geriatr Psych 1995;10:1059-1062
31. Wagg A, Wyndaele J-J, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4:14-24
32. Chapple CR, Drogendijk T, Wright M, Bolodeoku J. Responses to solifenacin in patients >65 years and
33. Cardozo L, Drogendijk T, Bolodeoku J. The efficacy of solifenacin 5/10 mg on 'urgency' endpoints in different OAB patient populations: subanalysis of results from the randomised, double-blind SUNRISE study. 38th Annual Meeting of the ICS, Cairo, Egypt, October 2008: abstract 192